Saturday 17 October 2026
Export TLIS’s income statement to Excel — free account
Talis Biomedical Corporation
TLIS Healthcare Medical Devices
Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.
2.84
0.00
0.00%
Follow TLIS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 54.60 | 6.32 | 4.35 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | 508.50 | 65.10 | 9.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 136 | 136 | 262 | 102 | 99 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.03 | 0.08 | 0.03 | 0.05 | 0.02 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 4 | 11 | 8 | 5 | 2 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | (74.38) | 98.08 | |||||
| EBT | — | — | — | — | (21) | (27) | (91) | (192) | (113) | (62) | |||||
| EBT margin, % | — | — | — | — | (892.76) | (690.82) | (833.15) | (2,343.90) | (2,348.55) | (2,905.67) | |||||
| Net income | — | — | — | 0 | (21) | (27) | (91) | (192) | (113) | (62) | |||||
| Depreciation | — | — | — | — | 1 | 1 | 1 | 2 | 9 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.67 | 77.52 | 77.36 | 5.42 | 2.67 | 1.17 | ||||
| Earnings | — | — | — | — | (6.00) | (536.08) | (642.57) | (127.14) | (63.57) | (34.12) | |||||
| Cash flow | — | — | — | — | (5.89) | (474.19) | (615.45) | (113.42) | (55.62) | (29.29) | |||||
| Capex | — | — | — | — | 0.00 | (11.27) | (58.00) | (1.90) | (0.90) | (0.27) | |||||
| Free cash flow | — | — | — | — | (5.89) | (485.46) | (673.44) | (115.31) | (56.52) | (29.56) | |||||
| Book value | — | — | — | — | 2.16 | (412.09) | (767.83) | 154.84 | 70.39 | 38.03 | |||||
| Shares, m | — | — | — | — | 4 | 0 | 0 | 2 | 2 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 5.39 | 5.39 | 5.39 | 11.09 | 2.75 | 6.85 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.39 | 0.10 | 0.21 | |||||
| EV/Sales | — | — | — | — | (10.44) | (10.44) | (10.44) | (17.29) | (24.31) | (29.11) | |||||
| EV/FCF | — | — | — | — | 1.20 | 1.20 | 1.20 | 0.81 | 1.15 | 1.16 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (21) | (24) | (87) | (171) | (100) | (53) | ||||
| Capex | — | — | — | — | (1) | (1) | (8) | (3) | (2) | 0 | |||||
| Free cash flow | — | — | — | — | (21) | (25) | (95) | (174) | (102) | (54) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 6 | 20 | 173 | 217 | 121 | 69 | ||||
| Total debt | — | — | — | — | — | — | 1 | 14 | 34 | — | |||||
| Net debt | — | — | — | — | (7) | (22) | (173) | (233) | (130) | (77) | |||||
| Shareholders’ equity | — | — | — | — | 8 | (21) | (109) | 234 | 127 | 69 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (375.06) | 142.18 | (81.32) | (82.73) | (51.95) | (46.98) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (8,371.86) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 58.34 | (72.14) | 140.51 | (306.27) | (62.66) | (63.32) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Mar 2024
Charts ten years each
Talis Biomedical Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MYO Myomo, Inc. | $51.5M | — (loss-making) | — (loss-making) | +21.26% (above 0%: growing) | n/m | +80.02% (above 0%: growing) | 72.13% | (19.26%) | Compare |
| COCH Envoy Medical, Inc. | $49.9M | — (loss-making) | — (loss-making) | −34.62% (below 0%: shrinking) | n/m | −22.44% (below 0%: shrinking) | (445.10%) | (10,919.61%) | Compare |
| MDAI Spectral AI, Inc. | $49.6M | — (loss-making) | — (loss-making) | −30.42% (below 0%: shrinking) | n/m | −21.86% (below 0%: shrinking) | 31.58% | (122.70%) | Compare |
| TLIS Talis Biomedical Corporation | $46.3M | — (loss-making) | — (loss-making) | −94.01% (below 0%: shrinking) | n/m | +23.80% (above 0%: growing) | 91.78% | 0.00% | |
| SRTS Sensus Healthcare, Inc. | $45.6M | — (loss-making) | — (loss-making) | −68.69% (below 0%: shrinking) | n/m | −201.65% (below 0%: shrinking) | 33.58% | (138.86%) | Compare |
| TELA TELA Bio, Inc. | $45.6M | — (loss-making) | — (loss-making) | −4.49% (below 0%: shrinking) | n/m | −17.72% (below 0%: shrinking) | 72.77% | (48.12%) | Compare |
| SNWV Sanuwave Health Inc. | $44.5M | 3.0× | — (loss-making) | −3.13% (below 0%: shrinking) | n/m | +86.75% (above 0%: growing) | 76.23% | (2.88%) | Compare |
| XTNT Xtant Medical Holdings, Inc. | $42.5M | — (loss-making) | — (loss-making) | −34.96% (below 0%: shrinking) | n/m | −881.96% (below 0%: shrinking) | 57.88% | (39.81%) | Compare |
| RPID Rapid Micro Biosystems, Inc. | $42.4M | — (loss-making) | — (loss-making) | +10.91% (above 0%: growing) | n/m | −23.97% (below 0%: shrinking) | 15.05% | (152.99%) | Compare |
| Median of peers | $45.6M | — | — | −17.45% | — | −22.15% | 45.73% | (85.41%) |
Talis Biomedical Corporation (TLIS) key facts
- Concern: Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022.
- Talis Biomedical Corporation (TLIS) is a Medical Devices company in the Healthcare sector.
- As of April 1, 2026, TLIS traded at $2.84, a market capitalization of $46.3 million.
- Return on equity was −63.3% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −9.10 (distress zone) for fiscal 2023.